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Abstract
Objective
To characterize and quantify barriers towards the publication of academic drug trials.
Study design
We identified academic drug trials approved during a 3-year period (2004–2007) by the Dan-
ish Medicines Agency. We conducted a survey among the trial sponsors to describe the
rates of initiation, completion, and publication, and the reasons for the failure to reach each
of these milestones. Information on size and methodological characteristics of the trials was
extracted from the EudraCT database, a prospective register of all approved clinical drug tri-
als submitted to European medicines agencies since 2004.
Results
A total of 181 academic drug trials were eligible for inclusion, 139 of which participated in our
survey (response rate: 77%). Follow-up time ranged from 5.1 to 7.9 years. Most trials were
randomized controlled trials (73%, 95% CI 65–81%). Initiation and completion rates were
92% (95% CI: 88–97%) and 93% (95% CI: 89–97%) respectively. The publication rate of
completed trials was 73% (95% CI: 62–79%). RCTs were published faster than non-RCTs
(quartile time to publication 2.9 vs. 3.1 years, p = 0.0412).
Conclusions
Many academic drug trials are left unpublished. Main barriers towards publication were
related to the process from completion to publication. Hence, there is much to gain by facili-
tating the process from analysis to publication. Research institutions and funders should
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actively influence this process, e.g. by requiring the publication of trial results within a given
time after completion.
Introduction
Data and conclusions from clinical trials are only available to the public if they are published.
Nevertheless, it has been estimated [1, 2] that less than half of trials initiated by academic
researchers are published. Such underreporting may lead to ethical and scientific problems
such as erroneous conclusions due to publication bias, unnecessary repetition of trials, waste
of resources, and failure to fulfill the trial subjects’ anticipation of making a contribution to
medical knowledge [3–8]. It may also lead to the failure to discontinue the use of a less effective
drug or delay the introduction of a more beneficial drug.
All researchers are obligated to make the results of their clinical trials publicly available [9],
but limited knowledge is available on the completion and publication of academic drug trials.
Ioannidis found that 61% of government-funded HIV trials initiated in 1986–1996 were com-
pleted while 55% of completed trials were published [10]. Studies on drug trials generally dem-
onstrate high rates of trial initiation (range: 88–97%[11–15]) and completion (range: 61–95%
of initiated trials [10–14]), and lower rates of publication (range: 33–74% of completed trials
[10–14, 16]). However, academic drug trials are underrepresented in these studies as the
majority of drug trials are conducted by the drug industry. Knowledge on the barriers towards
the completion and publication of academic drug trials is needed to improve the reporting of
these trials.
It has been indicated that the process from initiation to completion is more critical than the
process from approval to initiation [17]. It is unknown whether the initiation and completion
rates of academic clinical drug trials are similar as are the reasons for the underreporting of
these trials.
The main objective of our study was to characterize and quantify the barriers towards publi-
cation of academic clinical drug trials by examining how many trials are initiated, completed,
and published. Secondarily, we describe the main reasons for the failure to reach each of these
milestones.
Material
In May 2012, we identified academic clinical drug trials from the EudraCT database [18]. The
database is a prospective registry of all clinical drug trials approved after 1 May 2004 by medi-
cines authorities in the European Community. The European Medicines Agency kindly pro-
vided an extract from the EudraCT database based on these inclusion criteria: clinical drug
trial applications submitted to the Danish Medicines Agency after 30 April 2004 and uploaded
to the database no later than 1 May 2007, sponsor status: non-commercial (see Fig 1). We
excluded sponsors that were not resident in Denmark and trial applications approved after 30
April 2007. There were no restrictions regarding funding or phase (I-IV). We defined a trial
as academic if trial data and publication rights seemed to belong to a publicly employed
researcher and if no company was named on the front page of the protocol. We have previ-
ously confirmed the consistency between our definition and the classification as ‘non-com-
mercial’ in the EudraCT database [1, 2]. The dataset contained information on sponsor’s
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name, sponsor’s contact details, randomization, blinding, design, control groups, and planned
number of trial subjects. The contact information for each sponsor was updated with informa-
tion from a registry of Danish physicians or from searching the internet.
The study was notified to the Danish Data Protection Agency (ID: BBH-2011-23 ACo). Eth-
ical approval was not required according to Danish law.
Method
The number of trials that were initiated, completed, and published was collected from a survey
among sponsors of academic drug trials. We also asked about the statistical significance of the
trial results. The characteristics of each trial in terms of randomization, blinding, design, con-
trol groups, and planned number of trial subjects were extracted from the EudraCT dataset.
We determined the medical specialty from the protocol title, the sponsor, and the sponsor’s
affiliation.
The survey was launched 4 June 2012 using an internet-based survey software, Enalyzer1.
This date was used as the cut-off for the survey. Each sponsor was asked if at least one subject
had been included in the trial (initiation milestone), whether the trial had been completed to
such an extent that a conclusion could be drawn (completion milestone), and whether the trial
was published in a PubMed-, EMBASE-, or Cochrane Library-indexed scientific journal or
Fig 1. Flow chart.
https://doi.org/10.1371/journal.pone.0172581.g001
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presented as a poster or similar with an associated indexed abstract (publication milestone). If
the trial was completed, the respondent was asked whether the trial conclusion was based on
statistical testing, and, if so, whether the outcome was statistically significant. The respondent
was also asked to state the reference(s) of associated publication(s). In case of failure to initiate,
complete, or publish a trial, the sponsor was asked to grade the influence of a number of sug-
gested reasons (see Table 1) and to fill in additional comments. The selection of reasons were
inspired by the findings of Chan [19], Decullier [20], and Weber [21].
Each sponsor was invited to participate in an electronic survey with a personalized email.
Reminders were sent after two and three weeks, respectively. Finally, a personalized paper
questionnaire was sent to each sponsor’s personal postal address with a stamped return enve-
lope. The second reminder and the paper questionnaire encouraged sponsors of non-initiated,
non-completed, and non-published trials to respond.
To roughly estimate the publication rate among trials of survey non-responders we con-
ducted a post-hoc literature search in PubMed. The search was based on the protocol title,
investigational drug(s), name of the sponsor, and EudraCT number.
Table 1. Reasons for non-initiation, non-completion, and non-publication of academic drug trials.
Degree of influence
Not at all
influential
n (%)
Slightly
influential
n (%)
Moderately
influential
n (%)
Very
influential
n (%)
Do not
know
n (%)
Missing
n
Reasons for non-initiation (n = 11)
Lack of time 5 (50%) - 3 (30%) 2 (20%) - 1
Lack of monetary resources 5 (50%) 2 (20%) 1 (10%) 2 (20%) - 1
Lack of study personnel 5 (50%) 2 (20%) 3 (30%) - - 1
Technical difficulties 6 (60%) 1 (10%) - 2 (20%) 1 (10%) 1
New results from other studies 7 (70%) 1 (10%) 1 (10%) 1 (10%) - 1
Lack of approval from ethics committee and/or
data protection agency
9 (90%) - - 1 (10%) - 1
Reasons for non-completion (n = 9)
Problems with the inclusion of subjects - - 2 (25%) 6 (67%) - 1
Drop out/withdrawal higher than expected 5 (63%) 2 (25%) 1 (13%) - - 1
Lack of time 6 (67%) - 3 (33%) - - -
Lack of monetary resources 6 (67%) - 2 (22%) 1 (11%) - -
Lack of commitment at one or more study sites 6 (75%) - 1 (13%) 1 (13%) - 1
Technical difficulties 7 (88%) - - 1 (13%) - 1
Trial ongoing 8 (100%) - - - - 1
Reasons for non-publication (n = 20)
Data analysis is ongoing 8 (40%) 1 (5%) 2 (10%) 8 (40%) 1 (5%) -
Manuscript is under preparation 7 (35%) 2 (10%) 4 (20%) 5 (25%) 2 (10%) -
Lack of time 10 (50%) 2 (10%) 1 (5%) 6 (30%) 1 (5%) -
The result has been communicated otherwise 12 (60%) - 2 (10%) 5 (25%) 1 (5%) -
The result is not interesting 11 (55%) - 5 (25%) 1 (5%) 3 (15%) -
The result is not statistically significant 9 (45%) 1 (5%) 4 (20%) 1 (5%) 5 (25%) -
The results are negative 9 (45%) 1 (5%) 4 (20%) 1 (5%) 5 (25%) -
Lack of monetary resources 12 (60%) 2 (10%) 3 (15%) 1 (5%) 2 (10%) -
Lack of study personnel 14 (70%) - 3 (15%) 1 (5%) 2 (10%) -
Manuscript has been submitted, but was rejected 17 (85%) - - 1 (5%) 2 (10%) -
https://doi.org/10.1371/journal.pone.0172581.t001
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Analysis
Numbers of initiated, completed, and published trials were listed with cumulative and condi-
tional probabilities. Reasons for not reaching each milestone were tabulated as frequencies and
percentages.
We calculated time to publication as the time from the date of approval by the Danish Med-
icines Agency to the date of acceptance of the first manuscript presenting trial results or, if
unavailable, the date of online or paper publication. Time to publication was analyzed using a
Cox proportional hazards model, log-rank test, and Kaplan-Meier plots. Trials not published
by the launch of the survey (June 4 2012) were censored. Pre-specified covariates were RCT/
non-RCT, medical specialty, institution, and type of study (exploratory or confirmatory). We
decided post-hoc to include year of approval (i.e. the year in which the clinical trial application
was approved by the DHMA) as a covariate and furthermore we did not conduct the analysis
with type of study. The association between the statistical significance of trial outcomes and
time to publication was analyzed in a 2x2-table with Fischer’s exact test. P-values <0.05 were
considered statistically significant.
Information on medical specialty, randomization, blinding, design, control groups, and
number of planned subjects were listed with frequencies and percentages. Differences between
published and unpublished trials were analyzed with χ2 and Fisher’s exact tests.
Data were analyzed in SAS 9.2, GraphPad Prism 6, and GraphPad QuickCalcs. A follow-up
interview study among sponsors of non-published trials was planned but not conducted as the
number of non-published trials was lower than expected.
Results
Identification of trials and conduct of survey
Data from 227 trials were extracted from the EudraCT database, 181 of which fulfilled the eligi-
bility criteria (Fig 1). The survey was sent to the sponsors of 181 Danish academic clinical drug
trials. The internet-based survey resulted in 120 responses and 13 refusals including two
responses by email. These two sponsors gave informed consent to letting LB fill in the ques-
tionnaire during a telephone interview. A further 20 responses and one refusal were obtained
from the paper questionnaire. No response was obtained from the remaining 27 sponsors.
One trial was excluded due to logical errors (the respondent stated that the trial was not initi-
ated, did not answer the question regarding completion, stated that the trial was published,
and cited a publication, which we were not able to find). No logical errors were found in the
electronic survey data (the questions were filtered). The final sample consisted of 139 trials
(response rate 77%, 139/181). Some respondents had difficulty answering whether statistical
significance tests were conducted (2 of 119 completed trials) and whether these tests were sig-
nificant or inconclusive (3 of 104 completed trials with statistical significance testing), and left
these questions blank.
Characteristics of included trials
Most of the trials were randomized, double blind trials (Table 2). Both randomization and
blinding were more prevalent among the published than among the unpublished trials (ran-
domization 80% vs. 62%, p = 0.022, blinding 70% vs. 44%, p = 0.009). Beside the investigational
drug, a non-drug comparator was used in 36% of the trials while an active comparator or a pla-
cebo was used in 27% of the trials. Few trials (9%) included more than one type of control
group.
Publication of academic drug trials
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A total of 21 medical specialties were represented in the cohort. The five most frequent spe-
cialties were clinical oncology (n = 21), neurology (n = 21), anesthesiology (n = 15), gynecol-
ogy/obstetrics (n = 12), and endocrinology (n = 7), Table 2.
Initiation, completion, and publication of academic drug trials
By the end of follow-up on 4 June 2012, 84 trials were published, 50 were not published, and 5
had unknown publication status (Table 3). Overall, 61% (95% CI: 53–69%) of approved trials
were published. While 92% (95% CI: 88–97%) of the approved trials were initiated and 93%
(95% CI: 89–97%) of the initiated trials were completed, only 71% (95% CI: 62–79%) of the
completed trials were published. Sixteen of the 30 unpublished trials had been disseminated
otherwise, e.g. presented at a scientific meeting or conference. Rates of initiation, completion,
and publication were similar across the period under study (Table 4).
Table 2. Characteristics of included academic drug trials by publication status.
All
n = 139
Published
n = 84
Unpublished
n = 50
p-value‡ Publication status unknown
n = 5¤
Controlled trials 110/133 (83%) 71/83 (86%) 37/46 (80%) 0.45 2
Missing 6 (4%) 1 (1%) 4 (8%) 0.06# 1
Controlled trials: Randomization 92/109 (84%) 64/71 (90%) 26/36 (72%) 0.01 2
Missing 1/110 (1%) 0/71 (0%) 1/37 (3%) 0.35# 0
Controlled trials: Blinding 67/105 (64%) 50/68 (74%) 16/35 (46%) 0.01 1
Missing 5/110 (5%) 3/71 (4%) 2/37 (5%) 1.00# 0
Controlled trials: Design
Parallel groups 30/101 (30%) 17/67 (25%) 12/33 (36%) 0.25 1
Cross-over 26/101 (26%) 24/67 (36%) 2/33 (6%) <0.01 0
Other design or combination of designs 10/101 (10%) 5/67 (7%) 5/33 (15%) 0.23 0
Missing 44/110 (40%) 25/71 (35%) 18/37 (49%) 0.18 1
Controlled trials: Control group interventions
Comparator other than active or placebo 45/107 (42%) 34/70 (49%) 10/35 (29%) 0.05 1
Active comparator only 19/107 (18%) 13/70 (19%) 6/35 (17%) 0.86 0
No comparator 19/107 (18%) 8/70 (11%) 11/35 (31%) 0.01 0
Placebo only 13/107 (12%) 9/70 (13%) 3/35 (9%) 0.75# 1
Active comparator and other comparator 6/107 (6%) 5/70 (7%) 1/35 (3%) 0.66# 0
Placebo and other comparator 3/107 (3%) 1/70 (1%) 2/35 (6%) 0.26# 0
Active comparator and placebo 2/107 (2%) 0/70 (0%) 2/35 (6%) 0.11# 0
Missing 3/110 (3%) 1/71 (1%) 2/37 (5%) 0.27# 0
Top five medical specialties*
1. Clinical oncology 20/139 (14%) 7/84 (8%) 13/50 (26%) 0.01 0
2. Neurology 21/139 (15%) 18/84 (21%) 3/50 (6%) 0.02 0
3. Anesthesiology 15/139 (11%) 12/84 (14%) 2/50 (4%) 0.06 1
4. Gynecology/obstetrics 12/139 (9%) 4/84 (5%) 7/50 (14%) 0.06 1
5. Endocrinology 7/139 (5%) 4/84 (5%) 3/50 (6%) 1.00 0
Median planned sample size 50 49 58 - 30
10th and 90th percentiles 16–200 12–150 20–238 - 20–108
‡χ2 test.
#Fisher’s exact test due to expected cell counts <5.
¤ Information was missing (n = 3) or conflicting (n = 2).
*Four trials had two medical specialties
https://doi.org/10.1371/journal.pone.0172581.t002
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Kaplan-Meier plots of time from approval to publication are shown in Fig 2. Median time
from approval to publication was 5.2 years (95% CI: 4.3–5.5). RCTs were published faster than
non-RCTs (p = 0.041, log-rank test). The median time from approval to publication of RCTs
was 4.2 years (95% CI: 3.7–5.1), but could not be computed for non-RCTs due to the low
Table 3. Conditional probability of initiation, completion, and publication of approved academic drug trials (success = the reaching of a given
milestone, failure = the failure to reach a given milestone).
Conditional probability Cumulative probability
Milestone n(failure) n(success) n(unknown) N of failure of success of success
Initiation 11 128 0 139 0.08 0.92 0.92
Completion 9 119 0 128 0.07 0.93 0.86
Publication 30 84 5# 119 0.25 0.71 0.61
# Information was missing (n = 3) or conflicting (n = 2).
https://doi.org/10.1371/journal.pone.0172581.t003
Table 4. Number and proportion of initiated, completed, and published academic drug trials by year of approval of clinical trial application.
All
trials
Initiated
trials
Completed
trial
Published
completed trials
Unpublished
completed trials
Publication status
unknown
Median time from
approval to publication
Year of
approval
n = 139 n = 128 n = 119 n = 84 n = 30 n = 5* Years (95% CI)
2004# 11 10 (91%) 9 (90%) 7 (78%) 1 (11%) 1 5.1 (1.3–5.4)
2005 54 49 (91%) 44 (90%) 27 (61%) 15 (34%) 2 5.2 (4.1–6.8)
2006 61 57 (93%) 54 (95%) 41 (76%) 11 (20%) 2 3.7 (3.0–5.0)
2007‡ 13 12 (92%) 12 (100%) 9 (75%) 3 (25%) - 4.2 (1.8–5.3)
#Trials submitted after 30 Apr 2004 and approved by 31 Dec 2004.
‡Trials approved 1 Jan 2007 to 30 Apr 2007.
*Information on publication was missing (n = 3) or conflicting (n = 2).
https://doi.org/10.1371/journal.pone.0172581.t004
Fig 2. Time from approval to publication of completed academic drug trials. (n = 114).
https://doi.org/10.1371/journal.pone.0172581.g002
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publication rate. Instead we compared the quartile time from approval to publication, which
was 2.9 years (95% CI: 2.5–3.3) and 3.1 years (95% CI: 1.3–5.3) for RCTs and non-RCTs
respectively (Fig 3).
Median time from approval to publication was not associated with the year of approval
(p = 0.07, log-rank test). However, we observed a tendency towards a shorter median time to
publication among trials approved in 2006 and 2007 than trials approved in 2004 and 2005
(Table 4).
According to the sponsors, statistically significant results were obtained in 69 of 91 (72%)
completed trials with known publication status and a conclusion based on the statistical testing
of a hypothesis. The publication rate was 84% among trials with a statistically significant result
compared to 86% among trials with a statistically insignificant result (OR 0.8; 95% CI: 0.2–3.3,
p = 1.00).
Reasons for non-initiation, non-completion, and non-publication are listed in Table 1.
Reasons for non-initiation. Eleven of the 139 approved trials were not initiated. Lack of
time was the most frequently stated reason (n = 5). Lack of study personnel and monetary
resources were stated as influential by five sponsors each. One sponsor stated that the trial was
abandoned because the regional GCP unit refused to monitor the trial due to ethical issues.
The sponsor also stated that the trial was approved by both the ethics committee and the Dan-
ish Medicines Agency. One sponsor stated that the trial was not initiated due to personal
reasons.
Reasons for non-completion. Nine studies were initiated but not completed. The most
frequent reason for this was problems with the inclusion of trial subjects. This was graded
moderately or very influential by the sponsors of eight of the nine non-completed trials. One
study was stopped prematurely due to side effects. One sponsor stated that the ethics commit-
tee’s demand for the listing of cancer as a potential side effect to the investigational drug in the
patient information leaflet made it almost impossible to find patients willing to participate.
Neither of the sponsors stated ‘trial ongoing’ as influential of non-completion.
Fig 3. Time from approval to publication of completed academic drug randomized controlled trials
(RCTs) and non-randomized controlled trials (non-RCTs).
https://doi.org/10.1371/journal.pone.0172581.g003
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Reasons for non-publication. The analysis of the reasons for non-publication was based
on the 20 unpublished trials that had neither been accepted for journal publication nor pre-
sented at a scientific conference or similar with an associated indexed abstract. The most fre-
quently given factors influential of non-publication was ongoing data analysis (11/20),
manuscript under preparation (11/20) and lack of time (9/20). Eight of the eleven responses
stating ongoing data analysis as influential of non-publication had chosen ‘highly influential’.
Similarly, ‘highly influential’ was chosen by five of the 11 respondents deeming the ongoing
manuscript preparation as influential. One respondent explained that the results of the trial
were indeed interesting, but as other parts of the respondent’s job were now more demanding
than when planning the trial, the publication process had slowed down. Lack of time was the
third most frequent reason deemed influential of non-publication with six of the nine respon-
dents grading lack of time as highly influential. One respondent wrote that the trial was still
including subjects.
The literature search for publications from the 41 non-responders yielded a publication
rate of 41% (17/41).
Discussion
We found an overall publication rate of 61% (71% of completed trials) by surveying sponsors
of approved academic drug trials. Almost all approved trials were initiated and completed.
Hence, the process from completion to publication seems more problematic than does the pro-
cess from approval to completion of a trial. Main reasons for non-publication of completed tri-
als indicated that data analysis and manuscript preparation were often still going on. Reasons
for non-initiation were mainly related to lack of resources while non-completion was primar-
ily related to problems with the inclusion of trial subjects.
The initiation and completion rates observed in our study (92% and 93%, respectively)
seem comparable to those previously reported from cohorts of clinical drug trials [10–14, 16].
High initiation and completion rates may indicate that planned trials are feasible and only few
barriers not overcome during the conduct of academic drug trials. This would support our
previous results showing that academic researchers are able to conduct drug trials under the
same comprehensive regulation as the drug industry [2].
We found a publication rate of 61% of approved trials (71% of completed trials), which
seems high compared to previous studies (range: 33–74% of completed trials [10–14, 16]) and
comparable to a recent study by van den Bogert (clinical drug RCTs approved by Dutch Inde-
pendent Review Boards in 2007)[15]. The difference to previous studies may be attributed to
several factors: Firstly, the publication rate may have increased over time. Our cohort of trials
approved in 2004–2007 comprise more recent trials than those studied by Suñe´[11] (drug trials
approved in 1997–2004), Hole [16] (drug trials approved in 2000), Berendt [1] (academic drug
trials submitted in 1993–2005 and 1999–2003), Decullier [12] (drug trials approved in 1994),
Ioannidis [10] (non-commercial HIV drug trials initiated in 1986–1996), von Elm [13] (drug
RCTs approved in 1989–1998), and Bardy [14] (drug trials approved in 1987). Since then the
framework for the conduct of clinical drug trials has changed remarkably. These changes
include the demand by the International Committee of Journal Editors (ICMJE) to prospec-
tively register clinical trials initiated after 1 July 2005 in a publicly available database [22]. They
also include the obligation for all drug trials conducted in the European Community to adhere
to the principles of Good Clinical Practice (ICH-GCP)[23]. Thirdly, the publication rate of
academic drug trials may be higher than that of commercial drug trials. This is supported by
data from von Elm showing that non-commercial funding was associated with an increased
probability of publication [13], but contrasts the publication rates reported by Hole et al [16]
Publication of academic drug trials
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of 73% and 75% among ‘sponsored’ and ‘non-sponsored’ completed trials respectively.
Fourthly, sponsors of published trials may have been more likely to respond to our survey than
the sponsors of non-published trials. This would inflate the observed publication rate. How-
ever, combination of the observed publication rate (61%, 84/139) with that of the PubMed
search for publications of the trials of non-responders (41%, 17/41) yielded a publication rate
of 56% (101/180). Although this is a rough estimate, it suggests the inflation of the observed
publication rate to be of limited size. We found no indication that the risk of bias in our study
is different from previous studies of drug trials. The response rate of 77% (139/181) is compa-
rable to the response rates obtained in previous studies (median: 100%, range: 67–100%).
The observed difference in the time from approval to publication of RCTs and non-RCTs
may reflect underlying differences between the two groups rather than the design itself. Oncol-
ogy trials are typically of long duration. They constituted 34% of non-RCTs (16/47), but only
4% of RCTs (4/92). This bias would probably have been minimized had we used the time from
completion to publication instead of the time from approval to publication. However, the time
of approval is better documented than the time of completion, which may be subject to recall
bias.
We observed a tendency towards a reduction in the time from approval to publication from
2004 to 2007. A larger sample is needed to evaluate whether this reflects an actual shortening.
Other factors than the efficiency of researchers may have influenced the observed time to pub-
lication, e.g. a shift towards more short-term trials and fewer long-term trials. Because we mea-
sured the time from approval rather than completion we could not differentiate the effect of
such changes from a change in the time used for the processing and publishing of trial results.
A Cochrane review found that trials with positive findings are published faster and more
frequently than other trials [3]. We did not observe an association between publication and the
presence of a statistically significant outcome when analyzing our data in a 2x2 table. Neither
did Callaham [24], but Schmucker et al. found an association between publication and direc-
tion of study findings in a large-scale meta-analysis of observational and interventional studies
[25]. The difference may be due to the limited sample size of our study, or to underlying differ-
ences in our narrow cohort compared to the broad cohort analyzed by Schmucker. In our
study, data on the statistical significance of trial results originated from the survey respondents
and may hence be associated with a degree of uncertainty.
Song [26] states that publication bias only arises when published studies are not representa-
tive of all studies conducted. But from an ethical point of view random non-publication is
problematic as well. The failure to publish a conducted study means that more trials will need
to be conducted, and more patients will be at risk of experiencing side effects or lack of treat-
ment effect. Furthermore, the completion of a trial is associated with a large build-up of knowl-
edge and the failure to publish the results may lead to a greater loss of knowledge and waste of
resources than the failure to initiate or complete a trial.
According to the trial sponsors, the main reasons for non-initiation were lack of resources
(time, money, personnel) while non-completion were mainly due to problems with the inclu-
sion of trial subjects. Main reasons for non-publication were ongoing data analysis or the prep-
aration of a manuscript. This is, however, no guarantee of future publication. In line with
previous findings [19, 27–29] few respondents (only one) stated the rejection of a manuscript
as influential on the failure to publish a trial. Decullier [12] also reported inclusion problems
as the main reason for non-completion, but other reasons for non-initiation and non-publica-
tion, e.g. confidentiality issues. The differences may be due to different composition of the two
cohorts as the study by Decullier primarily included commercial trials. In addition, numbers
of non-initiated, non-completed, and non-published trials are relatively small in both studies.
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Half of the unpublished trials had been disseminated at a conference or similar with an
associated indexed abstract. Thus, non-publication was not synonymous to non-dissemina-
tion, but only the indexing in bibliographic databases facilitates the systematic identification of
trial results by other researchers, reviewers, etc.
Strengths and limitations
Our study is the first to study the completion and publication of academic drug trials that were
conducted under the principles of Good Clinical Practice (GCP). A major strength is that we
studied the process in an inception cohort as described by Ioannidis [10] and Song [26] by
including all Danish academic clinical drug trials prospectively registered in the EudraCT
database. We believe that the vast majority of drug trials conducted in Denmark are registered
in the database. Large numbers of missing values—especially on design and blinding—may
limit the validity of some of our results. A check for consistency in the information on ran-
domization and the use of a control group showed that the information was consistent in 127
of 130 trials. Three trials had conflicting information as they were registered as both uncon-
trolled and randomized. Moreover, the proportion of controlled trials (83%), RCTs (73%) and
blinded trials (62%) in our study cohort seems comparable to our earlier findings of 79% con-
trolled trials, 68% RCTs and 47% blinded trials in a sample of Danish academic drug trials
approved from 1993 to 2005 [1].
Our results reflect the framework for clinical trials as it was when the trials in our cohort
were conducted and reported. Since then, new initiatives to improve transparency, accessibil-
ity and publication rates have been introduced. In 2011, selected information on clinical drug
trials approved by European medicines authorities was made publicly available [30]. Further-
more, sponsors of clinical drug trials in the European Community are now obliged to post
results-related information to the EudraCT database following end of trial [31]. Both protocol-
related and results-related data are publicly available from the EU Clinical Trials Register [30].
This will hopefully improve access to unpublished results. A major limitation is the lack of
indexing in bibliographic databases. Therefore, the data will not be easily available when
searching for literature.
Conclusion
The observed publication rate was higher than expected, but many academic drug trials are
still left unpublished. Main barriers towards publication were related to the process from com-
pletion to publication, e.g. data analysis and manuscript preparation still going on 5 to 8 years
after approval of a trial. This suggests that much may be gained by facilitating the process from
analysis to publication. Besides regulatory initiatives, research institutions and funders should
also actively influence this process, e.g. by requiring the publication of trial results within a
given time after completion.
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